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Abstract
Background: The fungal pathogen Cryptococcus neoformans is a leading cause of illness and death in persons with
predisposing factors, including: malignancies, solid organ transplants, and corticosteroid use. C. neoformans is ubiquitous in
the environment and enters into the lungs via inhalation, where it can disseminate through the bloodstream and penetrate
the central nervous system (CNS), resulting in a difficult to treat and often-fatal infection of the brain, called
meningoencephalitis. Plasminogen is a highly abundant protein found in the plasma component of blood and is necessary
for the degradation of fibrin, collagen, and other structural components of tissues. This fibrinolytic system is utilized by
cancer cells during metastasis and several pathogenic species of bacteria have been found to manipulate the host
plasminogen system to facilitate invasion of tissues during infection by modifying the activation of this process through the
binding of plasminogen at their surface.
Methodology: The invasion of the brain and the central nervous system by penetration of the protective blood-brain barrier
is a prerequisite to the establishment of meningoencephalitis by the opportunistic fungal pathogen C. neoformans. In this
study, we examined the ability of C. neoformans to subvert the host plasminogen system to facilitate tissue barrier invasion.
Through a combination of biochemical, cell biology, and proteomic approaches, we have shown that C. neoformans utilizes
the host plasminogen system to cross tissue barriers, providing support for the hypothesis that plasminogen-binding may
contribute to the invasion of the blood-brain barrier by penetration of the brain endothelial cells and underlying matrix. In
addition, we have identified the cell wall-associated proteins that serve as plasminogen receptors and characterized both
the plasminogen-binding and plasmin-activation potential for this significant human pathogen.
Conclusions: The results of this study provide evidence for the cooperative role of multiple virulence determinants in C.
neoformans pathogenesis and suggest new avenues for the development of anti-infective agents in the prevention of
fungal tissue invasion.
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Introduction
Invasion of the central nervous system (CNS) by penetration of
the blood-brain barrier (BBB) is essential for the establishment of
meningoencephalitis by the opportunistic fungal pathogen Crypto-
coccus neoformans, though the mechanism by which this organism
invades the BBB has not been definitively established [1–4].
Blood-born pathogens may enter the peripheral or CNS
compartments through multiple mechanisms of transmigration
across the vasculature that include intercellular (paracellular) and
transcellular passage, as well as a ‘‘Trojan horse’’ route in which
intracellular pathogen is transported across endothelial barriers
within host cells [5]. C. neoformans is a leading cause of illness and
death in persons with predisposing factors including: malignancies,
solid organ transplants, AIDS, autoimmune disease, diabetes,
corticosteroid use, and pregnancy [6–12]. C. neoformans is
ubiquitous in the environment and enters the lungs by inhalation,
with dissemination into the CNS, resulting in a difficult to treat
and often-fatal meningoencephalitis. Current drugs used to treat
this fungal infection have limited efficacy due to resistance,
toxicity, and reduced CNS bioavailability [13–16]. Although the
immunosuppressed are at greatest risk of infection and death,
healthy individuals can also contract the disease due to the
widespread presence of the fungus in the environment [17].
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5780The cell wall of C. neoformans is critically important for its
pathogenesis, as the polysaccharide capsule and melanin are cell
wall-associated virulence factors [18–22]. The fungal cell wall is
unique among cellular organelles in that it provides mechanical
strength and acts as a physical barrier to protect the cell from
damage. In addition to its structural role, the cell wall is also an
important mediator of events necessary for cell-to-cell recognition,
growth and morphogenesis, and additionally plays an important
role in host immune responses during fungal pathogenesis
(reviewed in [23–26]). Fungal cell wall proteins also contribute
to cell wall organization and stress-induced survival responses by
facilitating wall remodeling and signal transduction events within
this organelle. Results from recent studies have shown that the cell
wall protein repertoire of some fungal pathogens, including C.
albicans, specifically and directly modulate their capacity to
disseminate, in vivo, by subverting the function of soluble host
proteins, like plasminogen, and their associated enzyme systems
[27]. Compared to other well-characterized fungi, however, the
cell wall protein composition of C. neoformans is relatively
understudied, although several extracellular proteases and immu-
nomodulatory mannoproteins have been identified [28–36].
Plasminogen is an abundant protein found in the plasma
component of blood and is a central component of the fibrinolytic
system that counteracts procoagulative activities to maintain
proper flow and multi-system homeostasis. The soluble form of
plasminogen within blood plasma exists as an inactive proenzyme
that is subject to proteolytic cleavage and activation when cell
surface-bound. At its amino terminus, plasminogen consists of five
disulfide-linked, homologous repeats that form looped ‘‘kringle’’
structures, and a serine protease catalytic domain at its carboxy
terminal end [37–40]. The kringle domains of plasminogen
structure are ,80 amino acids in length and mediate the
attachment of plasminogen to cell surfaces by binding proteins
with accessible carboxyl-terminal or internal lysine residues.
Conversion of plasminogen to the protease, plasmin, is
mediated by host-expressed tissue-derived plasminogen activator
(tPA) and urokinase (uPA). Plasmin is a broad-specificity serine
protease that degrades fibrin and collagen, in addition to other
structural proteins. Plasmin also activates other proteolytic
enzymes, such as matrix metalloproteinases (MMPs), that degrade
the tight junction components of microvascular endothelial cells
[41]. This latter function is critical for plasmin-mediated
mechanisms of intercellular migration that allow passage of cells
across the vasculature into either peripheral tissues or otherwise
privileged compartments such as the central nervous system.
The minimal biochemical and structural requirements for
plasminogen recruitment predisposes the plasminogen system to
pathogen-manipulation for use during invasion of tissue barriers
[42]. The relative importance of plasminogen in infectious disease
is indicated by the surface-associated plasminogen-binding prop-
erties manifested by diverse species of human pathogens, including
Yersina pestis, Listeria monocytogenes, several species of Streptococcus, and
four pathogenic fungal species, C. albicans, Aspergillus fumigatus,
Paracoccidioides brasiliensis, and Pneumocystis jiroveci (carinii) [27,41,43–
48]. Several proteins have been found to play a major role in
microbial recruitment of plasminogen, including enolase, glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH), and phospho-
glycerate kinase (PGK). These are carbohydrate-active molecules
that, though predominantly found in soluble form within the
cytosol, are capable of localizing to bacterial and fungal cell walls
where they exhibit accessible carboxyl-terminal or internal lysine
residues for plasminogen binding [49]. By serving as key surface
receptors for plasminogen recruitment, these and other proteins
have been shown to function as central mediators of CNS invasion
and microbial virulence [44,46,49–55]. In this report we
demonstrate that C. neoformans is likewise capable of recruiting
plasminogen and activating the plasminogen-fibrinolytic system.
Moreover, we find this recruitment process occurs at physiolog-
ically relevant plasminogen concentrations and is mediated by
similar receptors that include cell wall-localized carbohydrate-
active proteins of cytosolic origin.
Materials and Methods
Strains and media
The strains used in this study were the following serotype D
strains of C. neoformans: JEC21 (MATa), JEC20 (MATa), B3501A
(MATa), FCH78 (MATa cap59::nat) and FCH79 (MATa CAP59
CA59::nat) and the serotype A (genotype A1/M1) strains C23 and
A1 38-2 [56]. All strains were grown in yeast extract-peptone-
dextrose (YPD) medium, unless otherwise noted. Sabouraud broth
diluted 1:10 in 16 phosphate-buffered saline (PBS) was used for
capsule induction, unless otherwise indicated.
Disruption of the C. neoformans CAP59 gene
The CAP59 gene was disrupted by homologous recombination
with a cassette containing the nourseothricin (NAT) resistance
marker [57,58]. The CAP59 gene (Accession L26508) was
amplified from JEC21 genomic DNA with primers FOX124 (59-
CTACGTCGAGCAAGTCAAGG) and FOX125 (59-AC-
CTAGGTTGCATGTGTTCC) to generate a 1.5 kbp product
(positions 830 to 2298) that was TOPO TA cloned into pYES2.1
(Invitrogen). The NAT cassette was amplified from the pDSF6
plasmid (NAT cassette in pCR2.1) with primers for use in yeast
gap repair to introduce 30 base regions of overlap from the CAP59
gene on either side of a unique Kpn1 site at position 1573
[FOX122 (59-TCGTCTTCATGAACGATATCTTGCCGCTG-
CGAGGATGTGAGCTGG) and FOX123 (59- ATTCAGT-
GTGGTGGAAGATTTGCGAAGAGAATGTAGAAACTA)].
The Kpn1-linearized CAP59-pYES2.1 plasmid and the amplified
NAT cassette were co-transformed into the S. cerevisiae strain
YPH499 to allow homologous recombination by gap repair and
Ura+ transformants were selected for analysis by colony PCR with
the flanking FOX 124/125 primer set. Recombinant plasmids were
isolated,and thecap59::natdisruptioncassettewas amplifiedwiththe
flanking primer set and introduced into the serotype D strainJEC21
by biolistic transformation. Disruption of the CAP59 gene was
confirmed by PCR analysis of genomic DNA isolates from
comparisons of wild-type (CAP59) and nourseothricin-resistant
transformants (cap59::nat) with the flanking primer set (FOX124/
125).
Plasminogen labeling
Strains were grown at 25uC in YPD to early log (24 hr), log
(48 hr) or stationary (72 hr) phases and washed in PBS. Unless
otherwise stated, 1610
8 cells were labeled with 100 mg purified
human plasminogen (Glu-plasminogen, Fitzgerald Industries) in
500 ml PBS with 1.5% BSA at 37uC for 0.5–2 hrs, washed twice in
cold PBS/BSA, then either used in additional experiments or
analyzed for plasminogen-binding by flow cytometry or Western
blot analysis. In some experiments, cells were treated for 30 min at
37uC with carboxypeptidase B (Sigma) or eACA (Sigma) before
labeling with plasminogen, after which reactions were further
incubated 1 hr (37uC) before washing. For sulfo-NHS-biotin
labeling, washed cells were incubated with 1 mg/ml sulfo-NHS-
biotin (Pierce) in PBS supplemented with 1 mM MgCl2 and
0.01 mM CaCl2 for 30 minutes on ice as previously described [59]
before or after plasminogen labeling.
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Approximately 1610
8 log phase cells were washed in PBS and
incubated with 100 mg plasminogen for 2–4 hrs at 37uCi nP B Sw i t h
1.5% BSA, in the presence or absence of 100 ng tissue plasminogen
activator (tPA) (Calbiochem) or aprotinin (Roche). After washing four
times in PBS to remove unbound plasminogen and tPA, the cells
were resuspended in SDS extraction buffer (50 mM Tris-HCl,
pH 8.0, 0.1 M EDTA, 2% SDS, 10 mM DTT) and boiled to release
surface-associated proteins, which were then fractionated by SDS-
PAGE, transferred to PVDF, and analyzed for plasminogen
conversion to plasmin by Western blot with anti-plasminogen.
Flow cytometry
Cells were cultured for 48 hr at 25uC in 50 ml YPD, washed
twice in PBS, and suspended at 10
6 in 500 ml PBS with 0.5% BSA
and plasminogen labeled as described above. Plasminogen-specific
rabbit antisera (Fitzgerald Industries), was diluted 1:1000 in a final
volume of 100 ml PBS and used to resuspend washed cell pellets.
After 1 hr incubation at 25uC, cells were washed twice in ice-cold
PBS and labeled with FITC-conjugated goat anti-rabbit IgG
secondary antibody (Antibodies Inc) for 30 min on ice then washed
as above. Cells were finally resuspended in 0.5 ml PBS before
analysis with a FACSVantage SE flow cytometer (BD Biosciences).
Data were analyzed with Cell Quest Pro software (BD Biosciences).
Because the vast majority of the log phase populations used in this
study demonstrated plasminogen-binding activity ($95%), the data
were not gated or otherwise manipulated.
Invasion assays
Approximately 1610
8 log phase cells of strain JEC21 were washed
in PBS and incubated with 100 mg plasminogen for 2–4 hrs at 37uC
in PBS, in the presence or absence of 100 ng tissue plasminogen
activator (tPA) (Calbiochem). After washing four times in PBS to
removeunboundplasminogenandtPA,thecellswereresuspendedin
RPMI and added to the upper chamber of BioCoat Matrigel invasion
chambers, an in vitro system for the study of cell invasion through
basement membrane consisting of BD Falcon
TM cell culture inserts
containing an 8 mm pore-size PET membrane coated with a uniform
layer of BD Matrigel
TM Basement Membrane Matrix (BD
Biosciences. Organisms were incubated in the upper well of the
transwell chamber for 24 hours at 37uCinahydrationchamberprior
to analysis of JEC21 penetration through the matrigel. Colony
forming units (CFU) per ml were determined by plating dilutions of
culture media from the lower well onto YPD, 37uC for 72 hours. At
least 4 replicates were used per condition tested.
Cell wall protein isolation
Cells (serotype D strains) were grown in 50 ml YPD at 25uC for
,48 hrtologphase. Cell pellets werewashed onceinPBSandonce
in sterile ultrapure water. Contaminating capsular polysaccharide
was removed by washing cell pellets in dimethyl sulfoxide (DMSO)
and incubating at room temperature for thirty minutes, two times.
Cell pellets were next washed twice in sterile ultrapure water to
remove residual DMSO. Cells were then frozen at 280uC for at
least 24 hr and suspended in ice-cold lysis buffer (10 mM Tris-HCl,
pH 7.4 with complete protease inhibitor (Roche). Cells were
mechanically lysed with 0.5 mm glass beads equal in volume to
frozen pellet and agitated on a Mini-beadbeater (Biospec Products)
for 12 cycles of 2 min treatment/1 min ice. To insure cell-breakage,
the supernatants were transferred to microtubes, placed in an ice/
salt/alcohol slurry and probe sonicated using a GE 130 Ultrasonic
Processor (Sonics and Materials, Inc) for 10 cycles of 15 sec
cavitation at a power setting of 30 W with 2 min off. Cell wall and
cytosol fractions were separated from the resulting homogenates by
centrifugation at 3000 g (13,000 rpm) for 10 min at 4uC using an
AccuSpin Micro R-minifuge (Fisher Scientific), and cell wall
fractions were incubated with progressively decreasing concentra-
tions of NaCl solution as described previously [60,61]. Cell wall
proteins were then extracted from cell wall fractions in SDS
extraction buffer by boiling at 100uC for 10 minutes. The resulting
extracts were clarified at 3000 g (13,000 rpm) and frozen at 280uC
prior to lyophilization (Dura-Dry MP Lyophilizer (FTS Systems)).
The lyophilized material was quantified by BCA protein assay
(Pierce) and stored at 280uC until use. Cell wall proteins obtained
by this method were used for identifying plasminogen receptors by
2D PAGE/plasminogen ligand blotting and 1D PAGE after
immunoprecipitation with plasminogen conjugated to CNBr-
activated Sepharose 4B (Amersham) beads, as described below.
One- and two-dimensional SDS-PAGE
1D SDS-PAGE was performed using the Novex system
(Invitrogen) with NuPAGE 10% bis-tris precast gels. Protein
samples were solubilized in NuPAGE LDS sample buffer in
0.005% beta-mercaptoethanol for 5 min at 100uC prior to SDS-
PAGE electrophoresis, followed by either protein transfer to
PVDF for Western blot analysis or visualization by silver stain
[62]. For 2D SDS-PAGE analysis, approximately 150 mg protein
sample was precipitated in 10% trichloroacetic acid in acetone at
220uC then washed in acetone and incubated again at 220uC.
Samples were dried in a centrivap concentrator (Labconco Corp)
and suspended in rehydration sample buffer (8 M urea, 2%
CHAPS, 50 mM DTT, 0.2% Bio-Lyte 3/10 ampholyte, 0.001%
bromphenol blue (Bio-Rad)) prior to 2D PAGE, as previously
described [60]. Duplicate gels were silver stained [62] or
transferred to PVDF for plasminogen ligand blotting.
Plasminogen ligand blotting and Western blot analysis
Plasminogen overlay: 2-D gels were transferred to polyvinyli-
dene difluoride (PVDF) membrane and blocked in PBS, 5%
blotto. Blots were incubated with human plasminogen at 2 mg/ml
in PBS. Plasminogen binding was detected with primary rabbit
anti-plasminogen anti-sera (Fitzgerald Industries) followed by
secondary goat anti-rabbit IgG-HRP conjugated antibody (Sigma)
and processed by autofluorography. For visualization and spot
isolation of plasminogen-binding proteins, blots were stained with
India Ink. Briefly, blots were washed two to three times in PBS,
0.3% Tween 20, and stained with India Ink in PBS, 0.3% Tween-
20 with gentle agitation overnight. Blots were finally washed in
several changes of PBS and rinsed in water to remove excess stain
and detergent before excision and spot-analysis by mass
spectrometry. Western Blot analysis: Electro-blotted PVDF
membranes were first incubated overnight at 4uC in PBS with
1.5% BSA and 0.07% Tween 20 then exposed for 1 hr (25uC) to
rabbit anti-human plasminogen (Fitzgerald Industries), diluted
1:1000 in PBS+1.5% BSA. Membranes were washed four times
with the same buffer and exposed to goat anti-rabbit HRP-
conjugated IgG antibody (Sigma) diluted 1:20,000 in
PBS+1.5%BSA for 1 hr, washed 46 in PBS-T, followed by
5 min incubation in Immuno-Star HRP substrate (Bio-Rad) and
detection by chemiluminescence.
Immobilization of cell wall protein with plasminogen-
conjugated sepharose beads
Lyophilized plasminogen was suspended in a solubilization
buffer (10 mM PBS, pH 7.4, 0.5% octyl glucoside and 0.1%
CHAPS) at 0.5 grams/ml and conjugated to CNBr-activated
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directions. Cell walls were prepared from 48 hr 50 ml YPD
cultures as described above, suspended in solubilization buffer at
1.5 mg/ml protein then added to plasminogen-conjugated beads
at a bead:protein ratio 1:2 (v/v) and tumbled for 1 hr at 25uC.
Beads were isolated by 10,000 g sedimentation for 1 min, and
washed three times in ice-cold solubilization buffer. Proteins were
released by boiling in protein sample buffer, fractionated by SDS-
PAGE and visualized by silver staining.
Protein identification by LC-MS/MS
Silver-stained protein spots or bands were manually excised with a
P2D1.5 pen (The Gel Company) from 2D and 1D gelsand destained
with a 1:1 working solution of 30 mM potassium ferricyanide and
100 mM sodium thiosulfate. Excised gel spots were washed in 250 ml
100 mM ammonium bicarbonate (Ambic) for 20 min., 500 ml5 0 %
acetonitrile(ACN): 50 mM Ambic for1 hr,50 mlA C N1 0m in ,t h e n
dried in a speed vacuum prior to trypsin digestion (10 ml1 0 0m M
Ambic with 0.2 mg trypsin (Promega)) overnight at 37uC. Peptides
were extracted twice in 150 ml5 %f o r m i ca c i d :6 0 %A C Nf o r1h r .
and pooled extracts were dried in a speed vacuum. Samples were
suspended in 20 ml 0.5% formic acid: 3% acetonitrile in water and
subjected to LC-MS/MS analysis. When necessary, protein spots
were excised manually from India ink-stained (1 ml/ml India ink,
0.3% Tween-20 in PBS) blots pre-wet in methanol, destained in 50%
methanolfor4 hrs,dried briefly,then digested with14 ml3 0 %A C N :
50 mM Ambic containing 0.1 mg/ml trypsin, overnight at 37uC.
Peptides were extracted with 50 ml 80% ACN by sonication for
15 min., dried in a speed vacuum, and resuspended in 20 ml5 %
formic acid: 3% ACN prior to LC-MS/MS analysis.
The peptide digests were analyzed by multidimensional microscale
capillary liquid chromatography coupled to an LTQ Proteome X
massspectrometer(ThermoFinnigan).Peptidemixtures(6.4 ml) were
loaded from the autosampler onto a 300 mm65 mmC 1 8t r a p
column (LC Packings) at a rate of 30 ml/min. and eluted from the
trap column with a 5–50% linear gradient of 0.5% formic acid in
80% ACNat a flow rate of 200 ml/min. The LTQ was run in positive
ion mode with a 1.8 kV tip voltage and a capillary voltage of 4 V.
Data were collected in a data-dependent mode with alternating MS
scan survey over the mass range of 600–3500 and five MS/MS scans
in exclusion dynamicmode. The spectrawere obtained with a 2.5 m/
z unit isolation window, relative collision energy of 35%, and a
dynamic exclusion duration of 5 min. The SEQUEST algorithm
within Bioworks rev3.3 (Thermo Finnigan) was used to search the
resulting spectra against a database containing a subset of the Swiss-
Prot and TrEMBL databases restricted for Cryptococcus neoformans
(10,464 entries: 291 from Swiss-Prot, 10,173 from TrEMBL) with the
following search parameters: peptide probabilities of less than 1.00e-
3, two or more unique peptides, peptide Xcorr minimum values of
1.5 (+1c h a r g e ) ,2 . 0( +2c h a r g e ) ,a n d2 . 5( +3 charge). One missed
trypsin cleavage was allowed. Permitted differential modifications
included oxidation of methionines (+16 Da).
Statistical analyses
Data are representative of at least three replicates and are
expressed as means+/2SEM. A value of p,0.05 or less was
considered statistically significant.
Results
Immobilization of plasminogen on the surface of C.
neoformans
In order to determine the plasminogen binding potential of C.
neoformans, we examined the ability of the JEC21 strain to both
bind plasminogen on its surface and facilitate the tPA-induced
activation of surface receptor-bound plasminogen to plasmin.
Surface binding was assessed by incubating plasminogen (Glu-
plasminogen) with intact log phase cells in the presence or absence
of the plasminogen activator tPA and the plasmin inhibitor
aprotinin prior to analysis of surface labeling by SDS-PAGE and
Western blotting. Western blot analysis of labeled cell extracts with
a polyclonal anti-plasminogen antibody showed that the single-
chain plasminogen was bound to cells and was converted to active
plasmin, as evidenced by the formation of the two-chain plasmin
form, in the presence of tPA (Fig. 1A, lanes 3–4). There was no
evidence of plasminogen conversion to plasmin in the absence of
added tPA, indicating that the serotype D strains of C. neoformans
do not express an endogenous plasminogen activator (Fig. 1A, lane
2). To ensure that the observed plasminogen labeling was a bona
fide feature of C. neoformans and not specific to the JEC21 strain,
duplicate reactions were performed for the related strains JEC20
and B3501A with identical results obtained for each (data not
shown). Additionally, the inclusion of aprotinin, in the presence of
Glu-plasminogen and tPA, prevented efficient plasmin-induced
cleavage of the amino-terminal activation peptide (8 kDa) from the
plasmin heavy chain (PlaH) and thus preventing the formation of
Lys-plasminogen, which is the form of plasminogen most readily
converted to active plasmin (Fig. 1A, lane 4) [63]. Analyses of
supernatants from the labeling reactions failed to detect plasmin-
ogen conversion in the absence of cells (data not shown),
demonstrating that surface receptor-mediated interactions are
required for plasmin activation.
Because the serotype A strains of C. neoformans have greater
clinical significance, we next examined plasminogen binding and
activation in the serotype A isolates C23 and A1 38-2. Both are of
the same genotype as strain H99 (A1/M1) and were obtained from
clinical (C23) and environmental (A1 38-2) sources. These strains
have been extensively characterized for their virulence phenotypes
(provided by Dr. Anastasia Litvintseva), and both display
comparable capsule sizes and levels of melanin production [56].
As we observed with the serotype D strains, the serotype A isolates
examined also displayed plasminogen binding at the surface
(Fig. 1B). Additionally, our results indicated that plasminogen
conversion to plasmin for the serotype A isolates did not occur in
the absence of added tPA, demonstrating that neither serotype (A
or D) expresses an endogenous plasminogen activator (Fig. 1B,
lanes 2, 5).
We next examined which surface-accessible structures (cell wall
and/or plasma membrane) mediate plasminogen binding. Log
phase cells were incubated with plasminogen and cell walls were
isolated in the absence of detergent and purified, following
extensive washing of the intact cells to remove unbound
plasminogen, and tested for plasminogen labeling. As the plasma
membrane and cell wall are tightly joined together, separation of
the two organelles is likely to require detergent solubilization.
Thus, to examine a possible role for plasma membrane-associated
proteins in the binding of plasminogen to C. neoformans, isolated cell
wall fractions were further treated with 0.5% Triton-X-100, and
the membrane pellets recovered from the detergent-soluble
fractions tested for plasminogen labeling. However, as indicated
in Figure 1C, plasminogen labeling was found exclusively in the
detergent-insoluble component of cell wall (Fig. 1C, lane 1),
suggesting a minor role, if any, for membrane-bound proteins
(Fig. 1C, lane 2) of cell wall-associated organelles, such as the
plasma membrane, in plasminogen binding. The specificity of
plasminogen detection was demonstrated by the absence of
plasmingen labeling in cells that were not incubated with
plasminogen prior to cell wall isolation (Fig. 1C, lanes 3–4).
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microorganisms by targeting the primary amine groups of cell-
surface proteins. We therefore tested the ability of molecules or
compounds that specifically target primary amines to inhibit
plasminogen surface interactions. Biotinylation reagents are useful
for this purpose because they target both a and e- amine groups,
thereby saturating all available cell-surface primary amines. The
activity of the sulfonate derivative of the amine-reactive N-
hydroxysuccinimide (NHS) ester of biotin used for these studies is
membrane impermeable and thus confined to cell surfaces [59]. As
shown in Figure 1D, cells that were first labeled with sulfo-NHS-
biotin concentrations of 10-fold or greater than that of
plasminogen failed to demonstrate plasminogen binding by
Western blot analysis. In contrast, when the labeling-order was
reversed so that cells received plasminogen prior to sulfo-NHS-
biotin, cells retained surface-bound plasminogen for sulfo-NHS-
biotin concentrations of up to 100-fold over that of plasminogen
(Fig. S1). These latter findings may be anticipated given that
plasminogen itself is rich in primary amines and thus capable of
interacting with and quenching the effective concentration of
sulfo-NHS-biotin applied in these experiments so that competitive
binding with plasminogen does not occur, confirming the
importance of C. neoformans cell-surface proteins in plasminogen
recruitment.
Plasminogen binding capacity of C. neoformans surface
receptors
The binding of C. neoformans to plasminogen was quantitatively
examined by flow cytometry and SDS-PAGE analysis. Both
approaches were used in this study to obtain an approximate
measure of ligand binding sensitivity and the relative limits of
plasminogen binding capacity. Flow cytometry histograms consis-
tently showed that $95% of (log phase) cell populations stained
positive for plasminogen. Surface plasminogen first became
detectable at plasminogen concentrations of 40 mg( ,10 mM) for
strains JEC21 (Fig. 2A) and B3501A (Fig. 2B) and was observed as
a slight shift in signal intensity over control populations not labeled
with plasminogen. A maximal shift in signal intensity occurred
with 120 mg( ,3 mM) plasminogen under the experimental
conditions applied. Of the two strains examined in these
experiments, B3501A consistently showed a greater binding
capacity for plasminogen by flow cytometry analysis, but this
difference was not significant and was evident only at plasmino-
gen-labeling concentrations of 80 mg or above (Fig. 2C).
We observed relatively high autofluorescence values for all C.
neoformans strains tested by flow cytometry that may have in turn
artificially elevated the range of plasminogen concentrations
required for label detection and characterization. We therefore
used SDS-PAGE and Western blotting to additionally examine the
plasminogen-binding activity of strains JEC21 and B3501A.
Under plasminogen labeling conditions similar to those applied
during flow cytometry, we found that surface plasminogen could
be detected at plasminogen labeling concentrations as low as 5 mg
(100 nM; Fig. 2D), which was ,10-fold lower than the minimal
labeling concentrations required for demonstrable binding by flow
cytometry analysis (Fig. 2C). Progressive increases in labeling
concentration resulted in correspondingly higher signal intensities
up to a maximal intensity with 80 mg plasminogen exposure (data
not shown). This latter value was ,30% lower than the maximal
Figure 1. Plasminogen binds selectively and specifically to the cell-surface of intact C. neoformans strains. (A–B) Conversion of
plasminogen (Plg) into plasmin heavy chain (PlaH) and light chain (PlaL) on the surface of intact C. neoformans serotype D and A strains. (A) Serotype
D strain JEC21 was incubated in the presence or absence of plasminogen, tissue plasminogen activator (tPA), and/or the plasmin inhibitor aprotinin
in phosphate-buffered saline with BSA. Cell wall proteins were released by boiling labeled cells in SDS-extraction buffer and fractionated by SDS-
PAGE, transferred to PVDF, and Western blotted with polyclonal anti-plasminogen antibody. Lane descriptions as follow: cells (JEC21) only (1), 100 mg
plasminogen (2), plasminogen and 100 ng tPA (3), plasminogen, tPA, and 1 unit aprotinin (4). (B) Serotype A strains C23 and A1 38-2 were incubated
in the presence or absence of plasminogen and/or tPA for 4 hrs at 37uC prior to Western blot analysis as described above. Lanes: cells (C23) only (1),
C23 with 15 mg plasminogen (2), C23 with plasminogen and 100 ng tPA (3), cells (A1 38-2) only (4), A1 38-2 with 15 mg plasminogen (5), and A1 38-2
with plasminogen and tPA (6). (C) Plasminogen associates with the cell wall of intact cells. Cells (1610
10) from log phase cultures (JEC21) were
incubated 4 hr at 37uC in the presence (lane 1) or absence (lane 3) of 50 mg plasminogen and separated into cell wall and cytosol components, as
described in Methods. Membranes (lane 2, 4) from cell walls were extracted and each fraction examined for the presence of plasminogen by Western
blot analysis. Sample loading was uniform at 5 mg per well. (D) Sulfo-NHS-biotin and plasminogen compete for cell-surface binding sites. Log phase
cells (JEC21) were initially labeled with sulfo-NHS-biotin in 0-, 1-, 10-, 100-fold molar equivalents of plasminogen then labeled 1 hr at 37uC with 50 mg
plasminogen (lanes 1–4, respectively).
doi:10.1371/journal.pone.0005780.g001
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similar numbers of cells. A 10-fold increase in the number of cells
per labeling reaction to 1610
8 resulted in a corresponding
decrease in the minimal concentration of bound plasminogen that
could be detected on intact cells by SDS-PAGE/Western blot to
10 nM (data not shown).
Given the crucial role of free surface a- and/or e-amine groups
in mediating the plasminogen interactions with C. neoformans,w e
further examined the effect of agents that selectively inhibit ligand
interactions with cell wall protein carboxy-terminal amine groups
using either competitive antagonism with the lysine analog eACA,
or the targeted cleavage of C-terminal lysines with carboxypep-
tidase B. The results shown in Figure 3 indicate a major role for
surface amine groups in facilitating surface protein-plasminogen
interactions. Cells pre-treated with carboxypeptidase B (Fig. 3A
and B) or 10-fold excess eACA (Fig. 3C) were no longer able to
bind plasminogen, as determined by both flow cytometry (Fig. 3A)
and Western blot analysis (Fig. 3B and 3C). Accordingly, these
data suggest a facilitating role for both internal and C-terminal
lysines residues present on surface proteins in plasminogen
recruitment by C. neoformans.
Influence of capsule on plasminogen binding and
activation
The surface-accessibility of wall-associated proteins, which serve
as receptors for binding of plasminogen in C. neoformans, may
change as cells age during culture, in vitro. Culture-dependent
changes in nutrient availability could, for example, modify
plasminogen binding activity through associated changes in cell
wall protein expression or their surface accessibility. We therefore
examined the plasminogen-binding ability of cells during lag
(24 hr) and stationary (72 hr) phases, using log phase (48 hr) cells
as a standard for comparison. Cells at different growth stages were
compared in parallel for relative plasminogen binding following
Figure 2. Plasminogen binding capacity of C. neoformans surface receptors. (A–B) Representative histograms for JEC21 (A) and B3501A (B)
cultured at 25uC for 48 hr in 50 ml YPD. Cells were suspended at 10
7/ml and labeled for 1 hr at 37uC with 40 mg (solid line), 80 mg (dashed line), or
120 mg (dotted line) plasminogen, followed by exposure to rabbit anti-human plasminogen antiserum and FITC-conjugated secondary antibody. The
numbers located above each curve in the histograms indicate plasminogen-labeling concentration (mg) for corresponding populations. Each
histogram shows cell number as a function of relative fluorescence obtained for a total of 10,000 events per population. The control population (bold
solid line) was treated with primary and secondary antibody in the absence of plasminogen labeling. Greater than 90% of the cells examined stained
positive for plasminogen under the growth conditions applied, so gating was not necessary. Each data set is representative of three independent
experiments. (C) Plasminogen binding curves for JEC21 (squares) and B3501A (closed triangles) cultured and plasminogen-labeled as in (A–B),
averaged from six independent experiments. Data were adjusted for nonspecific binding, which is represented by the baseline. (Kd JEC21=900 nM,
Kd B3501A=750 nM). (D) Plasminogen binding curve of JEC21 as detected by Western blot analysis from three independent experiments. Cells were
incubated with the indicated concentrations of plasminogen for 1 hr 37uC then examined for surface-bound plasminogen by Western blot analysis.
The graph shows the relative signal density detected for the plasminogen concentrations indicated on the abscissa. A representative blot is shown
with plasminogen concentrations (mg) concentrations indicated below each band.
doi:10.1371/journal.pone.0005780.g002
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observed maximum labeling concentration bound by log phase
cells in our experimental conditions (Fig. 2). Signal intensities from
flow cytometry histograms were quantified and presented in the
bar graph shown in Figure 4A, which indicates that a significant
variance in plasminogen binding does occur as cells progress
through different stages of growth. Notably, the highest plasmin-
ogen binding was observed for log phase (48 hr) cells (Fig. 4A). In
contrast, cells harvested during lag phase growth demonstrated less
than half the plasminogen binding activity of log phase cells, while
stationary phase cells exhibited a greater than 90% relative
decrease in plasminogen binding activity compared to log phase
cells (Fig. 4A).
As plasminogen recruitment and the plasminogen-activated
fibrinolytic system have been implicated in facilitating microbial
pathogenesis, we next examined the influence of capsule formation
on the cell wall surface accessibility and plasminogen binding
capacity of the serotype D strains JEC21, FCH78 (cap59::nat), and
FCH79 (CAP59 cap59::nat) and the serotype A isolates C23 and A1
38-2. Cell growthof each strainina PBS-diluted Sabouraudcapsule
induction medium, with the exceptionofthe cap59D isolate,resulted
in robust capsule formation, as shown for strain JEC21 (Fig. 4E),
validating the effectiveness of the capsule induction protocol. Post-
induction encapsulated strains were next examined for plasminogen
binding activity by SDS-PAGE/Western blot analysis. Encapsulat-
ed serotype A and D cells, incubated in the presence of
plasminogen, showed no plasminogen binding by Western blot
analysis (Fig. 4C, lane 5 and Fig. 4D, lanes 2, 4, 6, and 8) as
compared to uninduced (hypocapsular) (Fig. 4C, lane 2 and Fig. 4D
lanes 1, 3, 5, and 7) or genetically-derived acapsular (cap59D) cells
(Fig. 4D, lanes 9–10), which were positive for plasminogen label.
Interestingly, the relative plasminogen binding activity of the
acapsular cap59D strain was considerably more pronounced than
that of the hypocapsular (uninduced) controls. These results may
indicate that the changes in surface density associated with capsule
formation could mask or otherwise interfere with the accessibility of
proteins to plasminogen.
As treatment with DMSO has been shown to remove capsular
polysaccharides from encapsulated cells [64,65], we also examined
the potential for masked plasminogen binding on the cell wall
surface in the presence of intact capsule. Following incubation of
cells (encapsulated or the uninduced controls) with plasminogen,
washed cells were exposed to DMSO prior to Western blot
analysis of surface plasminogen labeling. Although DMSO-
treatment resulted in extensive capsule removal, as observed by
India Ink staining (data not shown), this treatment did not reveal
detectable plasminogen-binding on the underlying cell wall in
encapsulated cells (Fig. 4C, lane 6). Additionally, DMSO
treatment did not disrupt detection of plasminogen labeling on
the surface of uninduced (hypocapsular) cells (Fig. 4C, lane 3).
When encapsulated cells from strain JEC21 were examined for
plasminogen binding activity by flow cytometry, only a minor shift
could be detected in response to 120 mg plasminogen (Fig. 4B)
relative to log phase cells receiving the same amount of label
(Figs. 2A–B). Indeed, we found the minor shifts in the plasminogen
binding activity of both encapsulated and stationary phase cells to
be quantitatively similar. When we examined stationary phase
cells microscopically, prominent capsules were observed in strain
JEC21 (Fig. 4E). These data, together with results from Figures 4C
and D, suggest that capsule formation may occlude or otherwise
constrain the presentation of cell wall proteins and inhibit the
interaction of plasminogen with surface receptors, although factors
other than capsule formation may compromise the ability of
stationary phase cells to interact with plasminogen.
Figure 3. Surface-exposed lysines are required for plasminogen binding. (A–B) Influence of carboxypeptidase B pretreatment on
plasminogen binding. Cells were grown to log phase at 25uC and incubated 30 min at 37uC in the presence of carboxypeptidase B prior to a
subsequent incubation with 50 mg plasminogen for 1 hr at 37uC and examination by either: flow cytometry (A), or Western blot analysis (B). In (A), the
control population, indicated by a solid black line, was treated with primary and secondary antibody in the absence of plasminogen labeling. The
dashed line represents cells incubated in the absence of carboxypeptidase (0 units) prior to plasminogen labeling (50 mg), while the population
depicted by the solid gray line was pretreated with 10 units of carboxypeptidase prior to the addition of 50 mg plasminogen. In (B), carboxypeptidase
treatments (in units), prior to the addition of plasminogen, are labeled as control (0 U), 1 (1 U), 5 (5 U), and 10 (10 U) above each corresponding
sample lane. Plasminogen incubation for 1 hr at 37uC was followed by extensive washing and subsequent Western blot analysis of plasminogen
binding. (C) Effects of eACA pretreatment on plasminogen binding. Cells were incubated for 30 min at 37uC with eACA at 0, 0.5, 1, or 10 molar
equivalents in excess of the concentration of plasminogen used (20 mg, ,400 nM). Plasminogen was added after the initial eACA incubation,
followed by an additional incubation for 1 hr at 37uC and subsequent Western blot analysis of plasminogen binding. The molar ratios of
eACA:plasminogen are noted above the lanes for each corresponding sample. The data shown are representative of three independent experiments.
doi:10.1371/journal.pone.0005780.g003
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The observation of surface-associated binding and activation of
plasminogen to plasmin on the C. neoformans cell wall led us to
investigate the identity of the cell wall proteins that function as
receptors for plasminogen. An affinity chromatography approach
was used to isolate plasminogen-binding cell wall proteins from
purified cell wall-associated protein fractions. Cell wall protein
extracts were incubated with plasminogen-bound or unbound
CNBr-sepharose beads and profiles of proteins recovered from
both the bead material and wash supernatants were visualized by
silver staining of SDS-PAGE gels after 1D separation. Silver
staining revealed similar patterns for both B3501A and JEC21
strains in the presence of plasminogen (Fig. 5, data not shown). In
the absence of plasminogen, the bead pull down of cell wall
protein extracts failed to yield detectable protein. Bands were
excised from the silver stained gel and digested with trypsin to
release peptides for LC-MS/MS. Data from mass spectrometry
was filtered and searched with the SEQUEST algorithm against a
database containing a subset of the Swiss-Prot and TrEMBL
databases restricted for Cryptococcus neoformans, LC-MS/MS analysis
of the proteins recovered from plasminogen-CNBr beads suggest-
ed that a number of cytoplasmic proteins are located on the
surface of C. neoformans, where they play a role in plasminogen
recruitment, in vivo. The proteins identified from CNBr-
plasminogen eluates included functionally diverse proteins, such
as heat shock proteins 60 and 70, pyruvate kinase, phosphoglyc-
erate kinase, the ATP synthase alpha and beta subunits, and the
response to stress-related protein (Q5KJB0) (Table S1). Three of
the twelve proteins, including glucose-6-phosphate isomerase,
phosphoglycerate kinase, and the putative uncharacterized protein
Q55ZV5, are predicted to have carboxyl-terminal lysine residues.
We next sought to both confirm and to identify additional
plasminogen-associated surface receptors using a combination of
ligand affinity and proteomics. Cell surface-associated proteins,
which include noncovalently-bound and disulfide bridge-associat-
ed proteins, were isolated from cell wall fractions by SDS-
extraction and analyzed by two-dimensional gel electrophoresis
and silver staining [60,61]. The method of cell wall protein
isolation used in our study was chosen to enrich for the
identification of the subpopulation of cell wall proteins that
facilitate plasminogen binding through receptor-mediated inter-
actions, which include predominantly ‘‘atypical’’ or ‘‘non-
classical’’ cell wall proteins of cytosolic origin. Duplicate gels were
Figure 4. Effects of growth phase and capsule development on plasminogen binding activity of C. neoformans. (A) Plasminogen
binding capacity at distinct stages of cell growth in YPD culture media. Serotype D strain JEC21 was incubated for the times indicated in 50 ml YPD
and measured by flow cytometry for the ability to bind plasminogen. The data shown were quantified from flow cytometry histograms as the percent
plasminogen binding over control (abscissa) for each time point described (ordinate) and are representative three independent experiments. The 24,
48 and 72 hr time-points indicated correspond to lag, log and stationary growth phases, respectively. (B–D) Plasminogen binding activity of
encapsulated cells. Flow cytometry histogram (B) and PAGE/Western blot (C) showing little or no plasminogen binding activity for encapsulated
JEC21 cells compared to reduced capsule (uninduced and DMSO-treated) controls. Strain JEC21 was grown in either YPD (C; lanes 1–3) or capsule
induction (C; lanes 4–6) medium prior to labeling for: 1 hr (B) or 4 hr (C) at 37uC with 120 mg (B, broken line) or 100 mg (C; lanes 2–3, 5–6)
plasminogen. Lanes 3 and 5 of (C) were treated 1 hr with DMSO prior to receiving 100 mg plasminogen. Control cells (B, bold line; C, lanes 1 and 4)
received primary and secondary antibody in the absence of plasminogen labeling. (D) Western blot analysis of plasminogen binding activity for
serotype D strains JEC21, FCH79 (CAP59 cap59::nat), FCH78 (cap59::nat), and the serotype A strains C23 and A1 38-2. Cells were grown in YPD (2cap)
or capsule induction (+cap) medium, labeled with plasminogen, and subjected to Western blot analysis, as described above, Lanes: JEC21 2cap (1),
JEC21 +cap (2), FCH79 2cap (3), FCH79 +cap (4), C23 2cap (5), C23 +cap (6), A1 38-2 2cap (7), A1 38-2 +cap (8), FCH78 2cap (9), and FCH78 +cap
(10). (E) Examination of capsule formation. Aliquots of strain JEC21 were examined at log or stationary growth phases, or after incubation in capsule
induction medium, and examined for capsule by India ink staining at 406 magnification. Results are averaged (A) from three independent
experiments or representative of either two (D) or three experiments (B–C).
doi:10.1371/journal.pone.0005780.g004
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identify cell wall-associated plasminogen binding receptors and the
results compared to the protein pattern of the silver stained
counterpart (Fig. 6). Spots that corresponded to plasminogen-
binding proteins, as well as selected spots to serve as references,
were excised from the silver stained gel and digested with trypsin
to release peptides for LC-MS/MS. Additional spots were excised
from the PVDF membrane and similarly processed for both
additional data confirmation and if corresponding spots were not
detectable on the matching silver stained gel. As before, spectral
data was searched against a database restricted for C. neoformans,
facilitating the identification of ten plasminogen-binding proteins
and three additional reference proteins, listed in Table S2. While
four of the identified proteins; Hsp60 and 70, the ATP synthase
beta subunit, and phosphoglycerate kinase; were also found with
the affinity chromatography approach (Fig. 5, Table S1), there
were six additional proteins identified, including transaldolase,
fructose-bisphosphate aldolase, and glutamate dehydrogenase
(Table S2). Figure 7 and Table S3 show examples of MS/MS
data output and peptide quality parameters for the protein
identified from spot 12 (Q5KFU0, ATP synthase beta subunit). Of
the ten plasminogen-binding proteins identified with the ligand
affinity method, only one (phosphoglycerate kinase) was predicted
to contain a carboxyl-terminal lysine, suggesting that plasminogen
binding to a majority of the surface receptors could be mediated in
part by internal lysine residues, as demonstrated by the inhibition
of plasminogen binding by the lysine analog eACA (Fig. 3C).
Comparisons of the spot intensities between the silver-stained gel
and the corresponding ligand blot show that glutamate dehydro-
genase (Q5KL32, indicated by * in Fig. 6B) exhibited the highest
relative affinity for plasminogen among the reactive spots, even
though it was not detectable in the silver-stained 2D gel. Also
observed among the plasminogen-binding proteins was the linear
pattern of spots with the same MW but different isoelectric point
(pI) values, a pattern characteristic of isoforms that result from
differential post-translational protein modifications (Fig. 6). Pro-
teins with this feature included the heat shock proteins (Hsp60 and
70), as well as the ATP synthase beta subunit. Additionally, the
reference protein enolase, which did not bind plasminogen in this
study despite the presence of a carboxyl-terminal lysine residue,
also displayed the isoform cluster typically observed for this
protein.
Plasminogen-mediated ECM degradation
We next examined the ability of surface-bound plasmin to
facilitate penetration of C. neoformans through Matrigel, a
reconstituted extracellular matrix (ECM) preparation used in
BioCoat Matrigel invasion chambers, an in vitro system for the
study of cell invasion through basement membrane, consisting of
cell culture inserts containing an 8 mm pore-size PET membrane
coated with a uniform layer of Matrigel. Log phase JEC21 cells
(1610
8) were incubated in the presence or absence of plasminogen
and/or tPA, then washed to remove unbound plasminogen and
added to the upper chamber of the transwell. The invasive
potential of JEC21 was determined by calculating colony-forming
units from medium in the lower chamber following 22 hrs of
incubation. Controls included cells that were not labeled with
plasminogen, as well as the omission of the plasminogen activator
tPA. In the presence of surface-bound active plasmin, C. neoformans
displayed detectable ability to penetrate the Matrigel into the
lower chamber compared to cells without bound plasminogen or
active plasmin (Fig. 8). This difference was statistically significant
(P,0.01) for the plasmin-labeled replicates compared to unlabeled
or plasminogen-only controls and suggests that C. neoformans may
utilize plasmin, a potent serine protease, to facilitate its invasive
potential across extracellular matrices.
Figure 5. Identification of plasminogen-binding cell wall proteins by 1D-PAGE and LC-MS/MS. Precipitation of purified cell wall protein
preparations made from strain B3501A with plasminogen-conjugated CNBr-sepharose beads. Protein profiles obtained from bead eluate fractions
(lane 1=fraction 1, lane 2=fraction 2) are compared after silver staining of 10% SDS-PAGE gels. Molecular weights are indicated on the left. The data
shown is representative of three experiments. Indicated are the positions of identified plasminogen-binding proteins. Identified proteins are listed in
Table S1.
doi:10.1371/journal.pone.0005780.g005
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The host plasminogen system is frequently exploited by
pathogenic organisms, both bacterial and fungal, to promote
tissue invasion and disease. In this study, we have shown that C.
neoformans binds plasminogen at its surface, facilitating the
activation of plasminogen to the broad-specificity serine protease
plasmin. Most significantly, we have also demonstrated the
importance of surface-bound activated plasmin in the invasion of
reconstituted extracellular matrix (ECM), in vitro, by C. neoformans.
We found that plasminogen binding to C. neoformans was strictly
cell wall-associated, with specific labeling demonstrated for the
surface of intact cells, as well as isolated cell wall fractions. The
binding of plasminogen was concentration-dependent for log
phase cells with affinities for both JEC21 and B3501A comparable
to those reported for C. albicans and bacterial pathogens such as the
Neisseria and Streptococcal species [44]. An intriguing observation
was the observed difference in the affinities of JEC21 and B3501A
for plasminogen. The observed dissociation constant (Kd) for
JEC21 was 900 nM, while the Kd for B3501A was found to be
750 nM, suggesting that the B3501A strain had a higher affinity
for plasminogen. While the significance of this finding is not
known, it may partially explain the differential virulence properties
associated with these two genetically similar strains [66].
The binding of plasminogen to the surface of C. neoformans was
found to be lysine-dependent, a feature that is common to all
plasminogen-binding species [41,49,67]. Treatment of C. neofor-
mans with basic carboxypeptidase, which cleaves exposed C-
terminal lysine residues, prevented surface-associated plasminogen
binding. Similar results were obtained following treatment with the
lysine analog eACA. Together, these results suggest that both
internal and C-terminal lysine residues present on the surface of C.
neoformans contribute to plasminogen recruitment and indicate that
the plasminogen receptor repertoire of C. neoformans is composed of
a diverse protein population.
The ability of C. neoformans to facilitate the conversion of bound
plasminogen to the serine protease plasmin was found to be
conserved among the serotype A and D strains tested, suggesting
that the observed virulence differences among the two serotypes,
as well as among strains within each serotype (JEC20, JEC21, and
B3501A for serotype D; and C23 and A1 38-2 for serotype A), are
independent of the ability to bind and activate plasminogen [66].
Additionally, the conversion of plasminogen to plasmin on the
surface of C. neoformans was dependent on the presence of the
Figure 6. Identification of plasminogen-binding cell wall proteins of C. neoformans by 2D-PAGE and LC-MS/MS. Two-dimensional gel
electrophoretic characterization of the cell wall proteome from a silver-stained gel (A), and the corresponding plasminogen-binding proteins (B) by
ligand (plasminogen) overlay and western blot analysis with anti-plasminogen antibody. Indicated are the positions of identified plasminogen-
binding proteins. Identified proteins shown in (B) are listed in Table S2. (* indicates spots sequenced following excision from the PVDF membrane due
to lack of detection by silver-staining).
doi:10.1371/journal.pone.0005780.g006
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neoformans does not express a functional plasminogen activator.
Thecryptococcalcapsuleisasignificantvirulencedeterminantand
serves to protect microorganisms from phagocytosis during infection
[68–71]. Since capsule formation may occlude or otherwise constrain
t h ep r e s e n t a t i o no fc e l lw a l lp r o t e ins and inhibit the interaction of
plasminogen with surface receptors, we compared the plasminogen-
binding activities for capsular, hypocapsular, and acapsular cells. As
might be expected, the absence of capsule promoted robust
plasminogen labeling, while the presence of capsule was sufficient
to prevent plasminogen binding at the cell wall surface. However,
factors that influence cell wall composition during capsule synthesis,
rather than the presence of capsule alone, may further compromise
the ability of encapsulated cells to interact with plasminogen.
While capsule formation is necessary for the development and
persistence of cryptococcal infection, there are several events during
the infection cycle in which the acapsular or minimally encapsulated
state would be advantageous, particularly during hematogenous
dissemination and endothelial cell interaction [1,72–74]. Therefore,
we propose that C. neoformans, like other encapsulated organisms,
including Neisseria meningitides and Streptococcus pneumoniae, which utilize
plasminogen recruitment to promote infection, may also exploit the
host plasminogen system during selected phases of the infection cycle,
such as dissemination and tissue invasion, when encapsulation is not
as favorable [75,76]. Finally, our results suggest that growth-related
changes in cell wall protein expression, as well as stress/virulence-
related changes in the topology of surface protein presentation, may
dynamically modulate the ability of this organism to interact with and
recruit plasminogen and possibly other plasma-derived mammalian
factors implicated in the progression of microbial disease, in vivo.
Figure 7. Identification of spot 12 as Q5KFU0, an ATP synthase beta subunit. Overview of identification is shown. Shaded areas (yellow in
graphical display and red for protein sequence) indicate peptide coverage. Shown as an inset is a representative MS/MS spectra for peptide
[LVLEVAQHLGENTVR] from Q5KFU0.
doi:10.1371/journal.pone.0005780.g007
Figure 8. Penetration of C. neoformans through reconstituted
ECM. The ECM invasion chambers are composed of matrigel (basement
membrane) layered on membranes with 8 mm pores. Strain JEC21 was
incubated with plasminogen in phosphate-buffered saline with BSA in
the presence or absence of tissue-derived plasminogen activator (tPA),
incubated in the upper chamber of the transwell for 24 hours at 37uC
prior to analysis of colony counts from the lower well (* (p=0.0093); **
(p=0.0084)).
doi:10.1371/journal.pone.0005780.g008
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both affinity chromatography and ligand binding permitted the
identification of several surface proteins that serve as plasminogen
receptors in C. neoformans. These include two proteins, phospho-
glycerate kinase (Pgk) and fructose bisphosphate aldolase (Fba),
previously identified as plasminogen-binding receptors in C.
albicans, as well as several proteins, including Hsp70, the ATP
synthase alpha and beta subunits, and glutamate dehydrogenase,
all of which have been previously reported to be localized to the
cell wall and/or cell wall transport vesicles (virulence bags) in C.
neoformans [44,77–79]. While the presence of cytosol-derived
proteins within the fungal cell wall has been extensively described,
the method by which these ‘‘moonlighting’’ proteins become
incorporated into the cell wall has not been established, as they
generally lack the classical signal sequences necessary for secretion
(reviewed in [25,80]) [61,81]. Although alternative secretion
pathways, adventitious binding, or cytosolic contamination have
all been suggested as possible explanations for the presence of
cytosolic proteins within the cell wall of various fungi, our findings
clearly show the specific localization of the plasminogen-binding
receptors within the cell wall of C. neoformans. The additional
discovery that several of these receptors, while of cytosolic origin,
are also found in cell wall transport vesicles or ‘‘virulence bags’’
suggests that C. neoformans manifests a complex secretion
mechanism that may facilitate the delivery of atypical cell wall
proteins, as well as other pathogenesis-related molecules [77].
Our findings also demonstrate the cell wall association of the
multifunctional protein enolase, a predominant plasminogen-
binding and cell wall incorporated protein in C. albicans, A. fumigatus,
and P. jiroveci (P. carinii) [45,46,82–87]. Although our results did not
corroborate a role for the importance of enolase in plasminogen-
binding in C. neoformans, we surmise that, due to the presence of a C-
terminal lysine and its relative abundance in the cell wall of C.
neoformans, enolase is indeed likely to contribute to plasminogen
binding, and our inability to detect binding was caused by the type
of plasminogen used in the ligand binding studies, as the affinity of
Lys-plasminogen for C-terminal lysines is substantially higher than
that of the Glu-plasminogen we utilized [63].
Functional studies to address the significance of surface-
associated plasminogen binding in the invasiveness of C. neoformans
demonstrated that plasmin-coated organisms possess an increased
potential to penetrate extracellular matrix, in vitro. Similar results
demonstrating the importance of plasminogen-binding have been
observed for other fungal pathogens. Most notable are the recent
studies demonstrating that susceptibility to invasive aspergillosis is
strongly influenced by the host plasminogen system and that
plasminogen activation on the surface of both A. fumigatus and C.
albicans promotes extracellular matrix invasion [46,48]. Although
multiple factors contribute to fungal virulence, including the
expression of extracellular proteases, morphogenic switching,
adherence, hydrolytic enzymes, and capsule production, the
conserved ability of fungal pathogens to subvert the host
plasminogen system suggests that plasminogen binding may be
an additional mechanism used by fungi to promote dissemination
and tissue invasion during infection [27,46,48,88,89].
In summary, we have shown that C. neoformans may utilize the
host plasminogen system to cross tissue barriers, providing support
for the hypothesis that plasminogen-binding could contribute to
the invasion of the blood-brain barrier by penetration of the brain
endothelial cells and underlying matrix. In addition, we have
identified the cell wall-associated proteins that serve as plasmin-
ogen receptors and characterized both the plasminogen-binding
and plasmin-activation potential for this significant human
pathogen. The results of this study provide evidence for the
cooperative role of multiple virulence determinants in C. neoformans
pathogenesis and suggest new avenues for the development of anti-
infective agents in the prevention of fungal tissue invasion.
Supporting Information
Figure S1 Plasminogen binds selectively and specifically to the
cell-surfaceof intactC. neoformans strainJEC21.Cells were labeled in
reverse-order to Figure 1C, with cultures first labeled with 50 mg
plasminogen, prior transferred to ice and incubation with sulfo-
NHS-biotin at 1-, 10-, 100-, 500-, or 1000-fold equivalent of added
plasminogen (lanes 1–5, respectively). Western blots of cell wall
proteins were prepared and first examined for plasminogen binding
(a) then stripped and re-examined for biotin (b). Arrows indicate
locationof90 kDamarker.Lane numbersarenotedaboveeachgel.
Each data set is representative of three independent experiments.
Similar results were obtained for strains JEC20 and B3501A.
Found at: doi:10.1371/journal.pone.0005780.s001 (0.15 MB TIF)
TableS1 Distinctbands (shownin Fig. 5)were excised, subjected to
trypsin digestion, LC-MS/MS analysis, and MS/MS spectra analysis
to identify each excised protein. Peptides were searched against the C.
neoformans protein database and results were filtered according to
peptide probabilities, SEQUEST X-corr (XC) scores, peptide charge
state, and two or more unique peptide hits per protein to eliminate
false or low-quality identifications. Locus ID, protein name, protein
molecular weight (MW), Sequest score (XC), percent sequence
coverage, and number of peptides identified amino are indicated for
each. * The affinity ligand plasminogen is included as an additional
control for peptide identification following spot excision.
Found at: doi:10.1371/journal.pone.0005780.s002 (0.03 MB
XLS)
Table S2 Plasminogen-binding spots and nonbinding controls
(spots shown in Figure 6) were excised, subjected to trypsin digestion,
LC-MS/MS analysis, and MS/MS spectra analysis to identify each
excised protein. Peptides were searched against the C. neoformans
protein database and results were filtered according to peptide
probabilities, SEQUEST X-corr (XC) scores, peptide charge state,
and two or more unique peptide hits per protein to eliminate false or
low-quality identifications. Locus ID, protein name, protein molec-
ular weight (MW), isoeletric point (pI), Sequest score (XC), percent
sequence coverage, and number of peptides identified amino are
indicated for each. Scores, coverage and # peptides are listed for a
single spot within an isoform cluster of identical proteins. Plasmin-
ogen-binding proteins listed in upper portion of table with
plasminogen-binding negative listed in lower portion (below line).
Found at: doi:10.1371/journal.pone.0005780.s003 (0.03 MB
XLS)
Table S3 Reference scan (Rscan), peptide sequence, mass to
charge ratio in positive ion mode (MH+), peptide charge (z),
peptide probability (PP), and Sequest score (X-corr).
Found at: doi:10.1371/journal.pone.0005780.s004 (0.67 MB TIF)
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